E. Ohman J or Asset Management AB Cuts Stock Holdings in McKesson Corporation $MCK

E. Ohman J or Asset Management AB reduced its stake in McKesson Corporation (NYSE:MCK) by 10.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,837 shares of the company’s stock after selling 676 shares during the period. E. Ohman J or Asset Management AB’s holdings in McKesson were worth $4,788,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of MCK. J.W. Cole Advisors Inc. grew its holdings in McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after buying an additional 1,329 shares in the last quarter. Private Wealth Partners LLC raised its holdings in shares of McKesson by 5.6% during the 3rd quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after acquiring an additional 1,682 shares in the last quarter. AlphaQuest LLC boosted its position in shares of McKesson by 91.2% during the 3rd quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after acquiring an additional 843 shares during the last quarter. CW Advisors LLC boosted its position in shares of McKesson by 282.5% during the 2nd quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after acquiring an additional 8,130 shares during the last quarter. Finally, Envestnet Asset Management Inc. grew its holdings in shares of McKesson by 12.4% in the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock valued at $255,438,000 after purchasing an additional 36,451 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling

In other McKesson news, Director Maria Martinez sold 349 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the transaction, the director owned 301 shares in the company, valued at $282,900.87. The trade was a 53.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Thomas L. Rodgers sold 276 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $816.18, for a total value of $225,265.68. Following the transaction, the executive vice president directly owned 2,268 shares in the company, valued at approximately $1,851,096.24. This represents a 10.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 3,868 shares of company stock worth $3,743,820 over the last three months. 0.08% of the stock is currently owned by company insiders.

McKesson Stock Down 0.8%

Shares of MCK opened at $878.61 on Tuesday. The business has a fifty day moving average of $904.74 and a 200 day moving average of $835.82. The company has a market cap of $107.62 billion, a PE ratio of 25.27, a P/E/G ratio of 1.43 and a beta of 0.38. McKesson Corporation has a 52-week low of $637.00 and a 52-week high of $999.00.

McKesson (NYSE:MCK) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business had revenue of $106.16 billion for the quarter, compared to analysts’ expectations of $105.98 billion. During the same quarter in the previous year, the business posted $8.03 earnings per share. The business’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. As a group, research analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, March 2nd. McKesson’s dividend payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on MCK shares. Leerink Partners restated an “outperform” rating and issued a $1,085.00 price target on shares of McKesson in a research report on Thursday, March 5th. Zacks Research cut shares of McKesson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 25th. Evercore restated an “outperform” rating on shares of McKesson in a report on Thursday, March 5th. Mizuho upped their target price on shares of McKesson from $880.00 to $885.00 and gave the company a “neutral” rating in a research report on Thursday, February 5th. Finally, Weiss Ratings downgraded shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a report on Thursday, February 5th. Thirteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, McKesson has a consensus rating of “Moderate Buy” and a consensus target price of $960.93.

McKesson Company Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.